“When doctors get liver chemistry results back and they’re out of whack, they should be aware to ask, ‘Were you taking CBD?’ Because a lot of people are.”
A new clinical trial suggests there are still ongoing questions about the safety of even low doses of cannabidiol, even as CBD capsules, gummies, edibles, oils and lotions have become increasingly omnipresent in the United States in recent years.
Dr. Watkins co-chairs the Drug-Induced Liver Injury Network. For more of Dr. Watkins' thoughts, read the story.
One of the research studies, Metabolism and liver toxicity of cannabidiol (Si Chen et al.), cited in this story can be found at https://pmc.ncbi.nlm.nih.gov/articles/PMC11404724/
